Bariatric Surgery Provides Long-term ...
Type de document :
Compte-rendu et recension critique d'ouvrage
PMID :
Titre :
Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis
Auteur(s) :
Lassailly, Guillaume [Auteur]
Hôpital Claude Huriez [Lille]
Institute for Translational Research in Inflammation - U 1286 [INFINITE (Ex-Liric)]
Caiazzo, Robert [Auteur]
Recherche translationnelle sur le diabète - U 1190 [RTD]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Ntandja-Wandji, Line-Carolle [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Gnemmi, Viviane [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Lille Neurosciences & Cognition - U 1172 [LilNCog]
Baud, Gregory [Auteur]
Recherche translationnelle sur le diabète - U 1190 [RTD]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Verkindt, Helene [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Ningarhari, Massih [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Louvet, Alexandre [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Leteurtre, Emannuelle [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 [JPArc]
Lille Neurosciences & Cognition - U 1172 [LilNCog]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Raverdy, Violeta [Auteur]
Recherche translationnelle sur le diabète - U 1190 [RTD]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Dharancy, Sébastien [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Pattou, François [Auteur correspondant]
Recherche translationnelle sur le diabète - U 1190 [RTD]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Mathurin, Philippe [Auteur correspondant]
Lille Inflammation Research International Center - U 995 [LIRIC]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Hôpital Claude Huriez [Lille]
Institute for Translational Research in Inflammation - U 1286 [INFINITE (Ex-Liric)]
Caiazzo, Robert [Auteur]
Recherche translationnelle sur le diabète - U 1190 [RTD]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Ntandja-Wandji, Line-Carolle [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Gnemmi, Viviane [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Lille Neurosciences & Cognition - U 1172 [LilNCog]
Baud, Gregory [Auteur]
Recherche translationnelle sur le diabète - U 1190 [RTD]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Verkindt, Helene [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Ningarhari, Massih [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Louvet, Alexandre [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Leteurtre, Emannuelle [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 [JPArc]
Lille Neurosciences & Cognition - U 1172 [LilNCog]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Raverdy, Violeta [Auteur]
Recherche translationnelle sur le diabète - U 1190 [RTD]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Dharancy, Sébastien [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Pattou, François [Auteur correspondant]
Recherche translationnelle sur le diabète - U 1190 [RTD]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Mathurin, Philippe [Auteur correspondant]
Lille Inflammation Research International Center - U 995 [LIRIC]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Titre de la revue :
Gastroenterology
Pagination :
1290 - 1301.e5
Éditeur :
Elsevier
Date de publication :
2020-10-31
ISSN :
0016-5085
Mot(s)-clé(s) en anglais :
Gastric Banding
Gastric Bypass
Roux-en-Y-Gastric-Bypass
Sleeve Gastrectomy
Gastric Bypass
Roux-en-Y-Gastric-Bypass
Sleeve Gastrectomy
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Background and aims: Studies are needed to determine the long-term effects of bariatric surgery for patients with nonalcoholic steatohepatitis (NASH). We evaluated sequential liver samples, collected the time of bariatric ...
Lire la suite >Background and aims: Studies are needed to determine the long-term effects of bariatric surgery for patients with nonalcoholic steatohepatitis (NASH). We evaluated sequential liver samples, collected the time of bariatric surgery and 1 and 5 years later, to assess the long-term effects of bariatric surgery in patients with NASH.Methods: We performed a prospective study of 180 severely obese patients with biopsy-proven NASH, defined by the NASH clinical research network histologic scores. The patients underwent bariatric surgery at a single center in France and were followed for 5 years. We obtained liver samples from 125 of 169 patients (76%) having reached 1 year and 64 of 94 patients (68%) having reached 5 years after surgery. The primary endpoint was the resolution of NASH without worsening of fibrosis at 5 years. Secondary end points were improvement in fibrosis (reduction of ≥1 stage) at 5 years and regression of fibrosis and NASH at 1 and 5 years.Results: At 5 years after bariatric surgery, NASH was resolved, without worsening fibrosis, in samples from 84% of patients (n = 64; 95% confidence interval, 73.1%-92.2%). Fibrosis decreased, compared with baseline, in samples from 70.2% of patients (95% CI, 56.6%-81.6%). Fibrosis disappeared from samples from 56% of all patients (95% CI, 42.4%-69.3%) and from samples from 45.5% of patients with baseline bridging fibrosis. Persistence of NASH was associated with no decrease in fibrosis and less weight loss (reduction in body mass index of 6.3 ± 4.1 kg/m2 in patients with persistent NASH vs reduction of 13.4 ± 7.4 kg/m2; P = .017 with resolution of NASH). Resolution of NASH was observed at 1 year after bariatric surgery in biopsies from 84% of patients, with no significant recurrence between 1 and 5 years (P = .17). Fibrosis began to decrease by 1 year after surgery and continued to decrease until 5 years (P < .001).Conclusions: In a long-term follow-up of patients with NASH who underwent bariatric surgery, we observed resolution of NASH in liver samples from 84% of patients 5 years later. The reduction of fibrosis is progressive, beginning during the first year and continuing through 5 years.Lire moins >
Lire la suite >Background and aims: Studies are needed to determine the long-term effects of bariatric surgery for patients with nonalcoholic steatohepatitis (NASH). We evaluated sequential liver samples, collected the time of bariatric surgery and 1 and 5 years later, to assess the long-term effects of bariatric surgery in patients with NASH.Methods: We performed a prospective study of 180 severely obese patients with biopsy-proven NASH, defined by the NASH clinical research network histologic scores. The patients underwent bariatric surgery at a single center in France and were followed for 5 years. We obtained liver samples from 125 of 169 patients (76%) having reached 1 year and 64 of 94 patients (68%) having reached 5 years after surgery. The primary endpoint was the resolution of NASH without worsening of fibrosis at 5 years. Secondary end points were improvement in fibrosis (reduction of ≥1 stage) at 5 years and regression of fibrosis and NASH at 1 and 5 years.Results: At 5 years after bariatric surgery, NASH was resolved, without worsening fibrosis, in samples from 84% of patients (n = 64; 95% confidence interval, 73.1%-92.2%). Fibrosis decreased, compared with baseline, in samples from 70.2% of patients (95% CI, 56.6%-81.6%). Fibrosis disappeared from samples from 56% of all patients (95% CI, 42.4%-69.3%) and from samples from 45.5% of patients with baseline bridging fibrosis. Persistence of NASH was associated with no decrease in fibrosis and less weight loss (reduction in body mass index of 6.3 ± 4.1 kg/m2 in patients with persistent NASH vs reduction of 13.4 ± 7.4 kg/m2; P = .017 with resolution of NASH). Resolution of NASH was observed at 1 year after bariatric surgery in biopsies from 84% of patients, with no significant recurrence between 1 and 5 years (P = .17). Fibrosis began to decrease by 1 year after surgery and continued to decrease until 5 years (P < .001).Conclusions: In a long-term follow-up of patients with NASH who underwent bariatric surgery, we observed resolution of NASH in liver samples from 84% of patients 5 years later. The reduction of fibrosis is progressive, beginning during the first year and continuing through 5 years.Lire moins >
Langue :
Anglais
Vulgarisation :
Non
Projet ANR :
Collections :
Source :
Fichiers
- document
- Accès libre
- Accéder au document
- S0016508520347582.pdf
- Accès libre
- Accéder au document